Document is current
Any future updates will be listed below
-
Authors
Mukherjee, Sudip
Kim, Boram https://orcid.org/0000-0002-4758-4547
Cheng, Lauren Y. https://orcid.org/0000-0001-7692-5446
Doerfert, Michael David
Li, Jiaming https://orcid.org/0000-0003-2051-9224
Hernandez, Andrea
Liang, Lily https://orcid.org/0000-0003-1907-6008
Jarvis, Maria I.
Rios, Peter D.
Ghani, Sofia
Joshi, Ira
Isa, Douglas
Ray, Trisha
Terlier, Tanguy
Fell, Cody
Song, Ping
Miranda, Roberto N. https://orcid.org/0000-0002-8467-5464
Oberholzer, Jose
Zhang, David Yu https://orcid.org/0000-0002-0213-7663
Veiseh, Omid https://orcid.org/0000-0003-1153-8079
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK120459)
U.S. Department of Health & Human Services | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK120459)
- License Information
-
More Information
Article History
Received: 23 February 2022
Accepted: 27 February 2023
First Online: 27 April 2023
Competing interests
: O.V. is cofounder and significant shareholder of Sigilon Therapeutics, Avenge Bio and Pana Bio. D.Y.Z. owns significant equity in and receives consulting income from NuProbe Global and Torus Biosystems, and owns significant equity in Pana Bio. J.O. is a founding scientist and significant shareholder of Sigilon Therapeutics and CellTrans Inc.
